Siemens targets molecular imaging in research pact:
This article was originally published in Clinica
Executive Summary
In a deal that signifies its investment in molecular imaging, Siemens Medical Solutions has agreed to dedicate resources, researchers and technology to the Center for Molecular Imaging Research (CMIR) at Massachusetts General Hospital. The CMIR focuses on combining genetic information and new chemistries to develop imaging probes, which are detectable by imaging technologies, to study diseases, such as cancer, atherosclerosis and rheumatoid arthritis. "The long-term goals of the collaboration are to develop novel technologies for in vivo sensing and imaging of molecular events, and to expand these new tools into clinical applications," says Dr Ralph Weissleder, the CMIR's director.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.